G
GRCE
Grace Therapeutics, Inc
2.360
+0.030+1.29%Opening09:59 06/10 EDT
OPEN/PREV CLOSE2.310/2.330
TODAY RANGE2.310-2.390
VOL4.48K
MARKET CAP36.52M
52 WEEK RANGE1.790-5.18
AVG VOL (3M)782.04K
% TURNOVER0.03%
TURNOVER--
P/E (TTM)-6.5428
% RANGE3.43%
EPS(TTM)-0.3607
P/E(FORWARD)-0.3809
P/B0.5628
BVPS4.194
DIVIDEND--
P/S33.92
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP26.55M
SHARES OUTSTANDING15.47M
NEXT EARNINGS06/26-07/02
FREE FLOAT11.25M
LOT SIZE1
EX-DATE07/10/2023
News
Press Releases
Financial Reports
Profile
TipRanks·4d ago
Grace Therapeutics VP of Clinical Operations Departs Role
Seeking Alpha·06/01 09:39
Grace Therapeutics: Assessing The Path Forward For GTx-104
TipRanks·05/12 14:42
Largest borrow rate increases among liquid names
TipRanks·04/27 11:30
Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress
Dow Jones·04/24 16:48
Grace Therapeutics Is Maintained at Buy by TD Cowen
Dow Jones·04/24 16:48
Grace Therapeutics Price Target Cut to $8.00/Share From $12.00 by TD Cowen
Benzinga·04/24 16:38
TD Cowen Maintains Buy on Grace Therapeutics, Lowers Price Target to $8
TipRanks·04/24 13:31
Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum
Benzinga·04/24 13:30
Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug
TipRanks·04/24 12:03
Grace Therapeutics price target lowered to $8 from $12 at TD Cowen
NASDAQ·04/24 06:21
FDA Issues CRL To Grace Therapeutics For GTx-104 In ASAH; Stock Down
TipRanks·04/23 18:57
Grace Therapeutics Receives FDA Complete Response for GTx-104
Same Industry
Name/Symbol
Change%
Price